User profiles for "author:A. Amit"
Arianna Maever L AmitUniversity of the Philippines Manila Verified email at up.edu.ph Cited by 11953 |
Five insights from the global burden of disease study 2019
CJL Murray, C Abbafati, KM Abbas, M Abbasi… - The Lancet, 2020 - thelancet.com
Summary The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019
provides a rules-based synthesis of the available evidence on levels and trends in health …
provides a rules-based synthesis of the available evidence on levels and trends in health …
Curcumin, a traditional spice component, can hold the promise against COVID-19?
The severity of the recent pandemic and the absence of any specific medication impelled the
identification of existing drugs with potential in the treatment of Coronavirus disease-2019 …
identification of existing drugs with potential in the treatment of Coronavirus disease-2019 …
[HTML][HTML] Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
T Vos, SS Lim, C Abbafati, KM Abbas, M Abbasi… - The lancet, 2020 - thelancet.com
Background In an era of shifting global agendas and expanded emphasis on non-
communicable diseases and injuries along with communicable diseases, sound evidence …
communicable diseases and injuries along with communicable diseases, sound evidence …
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
…, EA Rozeman, CU Blank, A Ronai, R Shaoul, A Amit… - Science, 2020 - science.org
Bacteria were first detected in human tumors more than 100 years ago, but the
characterization of the tumor microbiome has remained challenging because of its low …
characterization of the tumor microbiome has remained challenging because of its low …
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …
…, T Neunhöffer, M Pölcher, P Wimberger, A Amit… - The Lancet, 2017 - thelancet.com
Background Rucaparib, a poly (ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind …
…, G Sonke, F Joly, A Floquet, H Hirte, A Amit… - The lancet …, 2017 - thelancet.com
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients …
shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients …
Three-dimensional structure of an antigen-antibody complex at 2.8 Å resolution
The 2.8 Å resolution three-dimensional structure of a complex between an antigen
(lysozyme) and the Fab fragment from a monoclonal antibody against lysozyme has been …
(lysozyme) and the Fab fragment from a monoclonal antibody against lysozyme has been …
[HTML][HTML] Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019
Background Reducing the burden of death due to infection is an urgent global public health
priority. Previous studies have estimated the number of deaths associated with drug …
priority. Previous studies have estimated the number of deaths associated with drug …
[HTML][HTML] Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a …
H Wang, KM Abbas, M Abbasifard… - The Lancet, 2020 - thelancet.com
Background Accurate and up-to-date assessment of demographic metrics is crucial for
understanding a wide range of social, economic, and public health issues that affect …
understanding a wide range of social, economic, and public health issues that affect …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis …
…, A Covens, G Sonke, F Joly, H Hirte, A Amit… - The Lancet …, 2021 - thelancet.com
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
been shown to extend progression-free survival versus placebo when given to patients with …
been shown to extend progression-free survival versus placebo when given to patients with …